Physician profile

Romil Saxena

Anatomic Pathology & Clinical Pathology · Indianapolis, IN

NPI 1629035399

$20,847.96

in general payments reported to CMS, 2019-2025

6 companies · none reported in 2025

See the full distribution for Anatomic Pathology & Clinical Pathology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$20,425.00
Food and Beverage$285.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
E.R. Squibb & Sons, L.L.C. $12,000.00 2023
Perspectum Diagnostics LTD $5,175.00 2023 Livermultiscan
Astrazeneca Pharmaceuticals LP $3,250.00 2024 Enhertu
Astellas Pharma US INC $150.00 2024
Agilent Technologies, INC. $137.96 2019
Astrazeneca Uk Limited $135.00 2024

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Romil Saxena

$20,847.96

in general payments reported 2019-2025

Years
2019-2024
Top company
E.R. Squibb & Sons, L.L.C.

https://glasscript.com/doctor/1149980/romil-saxena

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.